Top Page
MedPlus Health Services Ltd.
(MEDPLUS)
MedPlus Health Services Ltd. (MEDPLUS) vs. iShares MSCI India ETF (INDA)
MedPlus Health Services Ltd. Business Overview & Revenue Model
MedPlus Health Services Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.90B | 61.36B | 56.25B | 45.58B | 37.79B | 30.69B |
| Gross Profit | 15.44B | 14.70B | 12.14B | 9.82B | 7.85B | 6.38B |
| EBITDA | 3.56B | 3.24B | 2.08B | 1.41B | 1.87B | 1.52B |
| Net Income | 1.78B | 1.50B | 654.73M | 497.63M | 958.02M | 638.58M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 33.60B | 30.05B | 27.97B | 25.94B | 15.66B |
| Cash, Cash Equivalents and Short-Term Investments | 3.67B | 4.40B | 1.65B | 2.89B | 6.58B | 1.49B |
| Total Debt | 0.00 | 11.20B | 10.10B | 9.00B | 8.15B | 5.90B |
| Total Liabilities | -17.40B | 16.20B | 14.27B | 13.06B | 11.77B | 8.35B |
| Stockholders Equity | 17.40B | 17.41B | 15.78B | 14.91B | 14.18B | 7.31B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.95B | 593.38M | -785.95M | 521.68M | -513.67M |
| Operating Cash Flow | 0.00 | 5.54B | 1.44B | 904.10M | 1.70B | 28.91M |
| Investing Cash Flow | 0.00 | -3.32B | -827.99M | 4.29B | -7.03B | -345.49M |
| Financing Cash Flow | 0.00 | -2.28B | -1.98B | -1.70B | 4.40B | -56.26M |
MedPlus Health Services Ltd. Technical Analysis
MedPlus Health Services Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ₹103.08B | 67.91 | ― | 0.20% | 22.34% | 20.71% | |
| ― | ₹103.33B | 275.51 | ― | ― | 16.85% | -29.57% | |
| ― | ₹263.68B | 50.51 | ― | 0.78% | 10.57% | 34.11% | |
| ― | ₹98.98B | 64.71 | ― | ― | 12.86% | 10.42% | |
| ― | ₹91.41B | 51.15 | ― | ― | 6.18% | 134.11% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | ₹26.35B | 96.22 | ― | 0.07% | -8.28% | -246.17% |
MedPlus Health Services Ltd. Corporate Events
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Karnataka and Telangana. These suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 1.51 lacs. This development may impact the company’s short-term financial operations but is unlikely to have a significant long-term effect on its market position.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two store locations in Karnataka. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 2.83 lacs. This development may impact the company’s financial operations and highlights regulatory challenges in maintaining compliance with drug and cosmetic regulations.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for a Drug License at its Telangana stores. The suspensions, issued by the Drugs Control Administration, Medchal, are due to violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The suspensions are expected to result in a potential revenue loss of approximately Rs 0.48 lacs and Rs 1.28 lacs for the affected stores. This development may impact the company’s financial operations and highlights regulatory compliance challenges within the industry.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received reaffirmed credit ratings from CareEdge Ratings Limited for both its long-term and short-term bank facilities. The ratings, CARE A; Stable for long-term and CARE A1 for short-term facilities, indicate a stable outlook and reflect positively on the company’s financial stability and operational capabilities.
MedPlus Health Services Ltd. has announced an earnings call scheduled for November 3, 2025, to discuss the unaudited financial results for the quarter and half-year ended September 30, 2025. This announcement is part of their compliance with SEBI regulations, and the call will be accessible to analysts and institutional investors, indicating the company’s commitment to transparency and stakeholder engagement.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a Drug License for one of its stores in Andhra Pradesh. The suspension, issued by the Drug Control Administration of Vizianagaram District, is for a duration of seven days and is expected to result in a potential revenue loss of approximately Rs 0.91 lacs. This development highlights a regulatory challenge for the company, potentially impacting its operations and financial performance in the region.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its store locations in Karnataka and Telangana. The suspensions, lasting five and three days respectively, are due to violations under the Drugs and Cosmetics Act and Rules. The company anticipates a potential revenue loss of approximately Rs 1.97 lacs, impacting its financial operations slightly. This development may affect the company’s operational efficiency and stakeholder confidence in the short term.
MedPlus Health Services Ltd. announced the successful completion of its 19th Annual General Meeting (AGM), where all proposed resolutions were approved by the members through remote e-voting and e-voting during the AGM. The results, along with the scrutinizer’s report, have been made available on the company’s website and the websites of the stock exchanges, indicating a smooth and compliant execution of the AGM proceedings.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Karnataka. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 1.06 lacs, impacting the company’s financial operations in the region.
MedPlus Health Services Ltd. has announced the completion of dispatching the notice for its 19th Annual General Meeting, which has been published in the ‘Financial Express’ and ‘Nava Telangana’ newspapers. This announcement is part of the company’s compliance with SEBI regulations and is accessible on their website and the websites of BSE and NSE, indicating their commitment to transparency and regulatory adherence.
MedPlus Health Services Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25, in compliance with SEBI regulations. This report, which is part of the company’s annual report, provides insights into MedPlus’s environmental, social, and governance (ESG) performance, highlighting its commitment to transparency and accountability in sustainable development.
MedPlus Health Services Ltd. announced the approval of its un-audited standalone and consolidated financial results for the quarter ended June 30, 2025. These results have been published in prominent newspapers and are available on the company’s website as well as on the BSE and NSE websites. This announcement reflects MedPlus’s commitment to transparency and compliance with SEBI regulations, potentially impacting investor confidence and market positioning.
MedPlus Health Services Ltd. has announced an earnings call scheduled for August 4, 2025, to discuss its unaudited financial results for the quarter ended June 30, 2025. This call is part of the company’s compliance with SEBI regulations and is aimed at engaging with analysts and institutional investors. The announcement underscores MedPlus’s commitment to transparency and maintaining strong communication with its stakeholders.